The Grand Slam Bundle

Overview

The Grand Slam Bundle groups three research materials, each characterized in a separate body of published work. It ships as three individual vials, two of which are themselves multi-peptide blends.

GLP3-R is retatrutide (LY3437943). Coskun et al. published its discovery-to-clinical-proof-of-concept characterization as a triple glucagon, GIP, and GLP-1 receptor agonist; Urva et al. reported the phase 1b multiple-ascending-dose study; and phase 2 trials in obesity and type 2 diabetes have appeared in NEJM and The Lancet.[1][2][3][4] It remains investigational with no regulatory approval.

GLOW combines GHK-Cu, BPC-157, and TB-500. Pickart and colleagues have reported that GHK-Cu coordinates Cu(II) and modulates broad gene-expression programs, and Maquart et al. reported stimulation of collagen synthesis in fibroblast cultures.[5][6][7] Hsieh et al. associated BPC-157's pro-angiogenic activity with VEGFR2 activation, and the TB-500 fragment carries the actin-binding motif of Thymosin β4.[8][10][11]

The CJC (no DAC) / Ipamorelin vial pairs two growth-hormone secretagogue research peptides that act at different receptors. The modified GRF(1-29) sequence derives from the work of Lance et al. on super-active GRF analogs and Soule et al. on D-Ala2 substitution.[12][13] Ipamorelin was described by Raun et al. as the first selective growth hormone secretagogue, acting at the ghrelin receptor.[17]

No peer-reviewed study has evaluated these three vials together as a bundle. Every citation on this page describes an individual component or blend studied on its own. Investigators should treat the kit as three separate research materials and consult the dedicated GLP3-R, GLOW, and CJC (no DAC) / Ipamorelin entries for complete mechanism, applications, and reference lists.

Reported Mechanisms — Component by Component

Each section below summarizes the published mechanism of a single component. No combined mechanism is described in the literature, and none is asserted here.

1. GLP3-R / Retatrutide (30 mg) — Triple Receptor Agonism

Retatrutide is described as engaging the GIP, GLP-1, and glucagon receptors with a single peptide sequence, distinguishing it from dual GIP/GLP-1 agonism and GLP-1-selective agonism.[1] Clinical pharmacology has been reported in phase 1b and phase 2 studies of the pharmaceutical formulation.[2][3][4]

2. GLOW (70 mg) — Three-Peptide Tissue-Repair Blend

GHK-Cu (50 mg) binds Cu(II); Pickart and colleagues have reported broad gene-expression modulation and matrix effects, and Maquart et al. reported stimulation of collagen synthesis in fibroblast culture.[5][6][7] BPC-157 (10 mg) has been associated with VEGFR2 activation in endothelial models, within the cytoprotection framework developed by Sikiric and colleagues.[8][9] TB-500 (10 mg) carries the LKKTETQ actin-binding motif of Thymosin β4; Philp et al. reported that a synthetic peptide containing this domain promoted dermal wound repair in rodent models.[10][11]

3. CJC (no DAC) / Ipamorelin (10 mg) — Two Receptors in the GH Axis

The two peptides in this vial act at different targets. The modified GRF(1-29) sequence is a growth-hormone-releasing-hormone analog; Lance et al. described super-active GRF(1-29)-amide analogs, and Soule et al. reported that D-Ala2 substitution increased half-life and decreased metabolic clearance.[12][13] Jetté et al. characterized CJC-1295 as a long-lasting GRF analog activating the GRF receptor on the anterior pituitary in rats, and Ionescu and Frohman reported that pulsatile GH secretion persists during continuous stimulation by the analog.[14][16] Ipamorelin acts instead at the ghrelin receptor (GHS-R1a); Raun et al. characterized it as the first selective growth hormone secretagogue, and Gobburu et al. published pharmacokinetic-pharmacodynamic modeling in human volunteers.[17][18]

No published pharmacokinetic, pharmacodynamic, or interaction study has evaluated retatrutide, the GLOW peptides, and the GH-secretagogue peptides administered together. Any combined behaviour is unstudied.

Research Applications (Component-Level)

The published work behind each vial in this kit falls into the following areas. Every study listed used a single component or blend, not the bundle.

1. Incretin and glucagon receptor pharmacology — retatrutide serves as the triple-agonist reference compound in comparisons against dual and selective agonists.[1][2]
2. Metabolic research — phase 2 trials of the pharmaceutical formulation have been published in obesity and type 2 diabetes.[3][4]
3. Matrix and fibroblast models — GHK-Cu has been studied for collagen synthesis and gene-expression modulation.[6][7]
4. Angiogenesis and wound-repair models — BPC-157 and the Thymosin β4 actin-binding fragment have each been examined in vascular and dermal repair paradigms.[8][11]
5. GHRH-receptor pharmacology — GRF(1-29) analogs have been characterized for receptor activation and half-life extension.[12][13][14]
6. Ghrelin-receptor pharmacology — ipamorelin has been characterized as a selective secretagogue and studied in rodent bone-growth and gastrointestinal-motility models.[17][19][20]
7. Analytical and doping-control chemistry — GRF analogs have been identified and characterized in confiscated preparations, which informs assay design.[15]

Important: no cited study used the combined bundle. Researchers should not assume that single-agent findings carry over to co-administration.

Research Summary (Component-Level)

No peer-reviewed study has evaluated this three-vial bundle as a unit. The table below lists representative findings for each component individually. Full per-component data and complete reference lists are on the dedicated GLP3-R, GLOW, and CJC (no DAC) / Ipamorelin pages.